{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:26:36Z","timestamp":1782714396963,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jsps.2022.06.010","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T15:53:37Z","timestamp":1655826817000},"page":"1193-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports"],"prefix":"10.1007","volume":"30","author":[{"given":"Eman A.","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadir","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waad","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2022.06.010_b0005","doi-asserted-by":"crossref","unstructured":"Abstracts of 48th ESCP symposium on clinical pharmacy 23\u201325 October 2019, Ljubljana (Slovenia): The digital revolution supporting clinical pharmacy through e-health, digital support systems, big data, and more, 2020. . Int J Clin Pharm 42, 217\u2013292. https:\/\/doi.org\/10.1007\/s11096-019-00945-w","DOI":"10.1007\/s11096-019-00945-w"},{"key":"10.1016\/j.jsps.2022.06.010_b0010","first-page":"57","article-title":"Ipilimumab-nivolumab therapy causing STEMI in a melanoma patient: a case report","volume":"4","author":"Alkhathlan","year":"2017","journal-title":"Case Rep. Intern. Med."},{"issue":"4","key":"10.1016\/j.jsps.2022.06.010_b0015","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Ando","year":"2019","journal-title":"Invest. New Drugs"},{"issue":"7","key":"10.1016\/j.jsps.2022.06.010_b0020","first-page":"2703","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna cancer and thrombosis study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.jsps.2022.06.010_b0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.jsps.2022.06.010_b0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2022.06.010_b0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2017.11.018","article-title":"Arterial thrombosis and anti-PD-1 blockade","volume":"91","author":"Boutros","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsps.2022.06.010_b0040","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"De-xiu","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jsps.2022.06.010_b0045","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.jsps.2022.06.010_b0050","doi-asserted-by":"crossref","first-page":"e93280","DOI":"10.1371\/journal.pone.0093280","article-title":"Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice","volume":"9","author":"Cochain","year":"2014","journal-title":"PLoS ONE"},{"issue":"01","key":"10.1016\/j.jsps.2022.06.010_b0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer","volume":"117","author":"Cohen","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jsps.2022.06.010_b0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.jsps.2022.06.010_b0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11523-018-0579-9","article-title":"Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries","volume":"13","author":"Ferreira","year":"2018","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jsps.2022.06.010_b0070","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.06.010_b0075","doi-asserted-by":"crossref","unstructured":"Gender differences in cancer patients with acute venous thromboembolism, 2015. . Thrombosis Research 135, S12\u2013S15. https:\/\/doi.org\/10.1016\/S0049-3848(15)50433-7","DOI":"10.1016\/S0049-3848(15)50433-7"},{"issue":"1","key":"10.1016\/j.jsps.2022.06.010_b0080","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jth.14630","article-title":"Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors","volume":"18","author":"Gervaso","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"22","key":"10.1016\/j.jsps.2022.06.010_b0085","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2003.05.165","article-title":"Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism","volume":"21","author":"Goldenberg","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsps.2022.06.010_b0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jsps.2022.06.010_b0095","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"issue":"15_suppl","key":"10.1016\/j.jsps.2022.06.010_b0100","doi-asserted-by":"crossref","first-page":"e20624","DOI":"10.1200\/JCO.2017.35.15_suppl.e20624","article-title":"Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab. American Society of","volume":"35","author":"Hegde","year":"2017","journal-title":"Clini. Oncol."},{"key":"10.1016\/j.jsps.2022.06.010_b0105","first-page":"4864","article-title":"Incidence of vascular thromboembolic events in patients receiving immunotherapy: A single institution experience","volume":"130","author":"Ibrahimi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jsps.2022.06.010_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-030-20315-3_6","article-title":"Thrombotic risk from chemotherapy and other cancer therapies","author":"Jiang","year":"2019","journal-title":"Thromb. Hemost. Cancer"},{"issue":"2","key":"10.1016\/j.jsps.2022.06.010_b0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.jsps.2022.06.010_b0120","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/jth.12725","article-title":"Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH","volume":"12","author":"Khorana","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jsps.2022.06.010_b0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010772","article-title":"Pembrolizumab-induced acute thrombosis","volume":"97","author":"Kunimasa","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jsps.2022.06.010_b0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsps.2022.06.010_b0135","doi-asserted-by":"crossref","first-page":"107818","DOI":"10.1016\/j.intimp.2021.107818","article-title":"Thromboembolic events associated with immune checkpoint inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database","volume":"98","author":"Li","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.jsps.2022.06.010_b0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Information J."},{"key":"10.1016\/j.jsps.2022.06.010_b0145","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0049-3848(10)70028-1","article-title":"Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management","volume":"125","author":"Mandal\u00e0","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jsps.2022.06.010_b0150","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/sj.bjc.6605091","article-title":"Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?","volume":"100","author":"Maraveyas","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"25","key":"10.1016\/j.jsps.2022.06.010_b0155","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jsps.2022.06.010_b0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/cancers12010067","article-title":"Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? mechanisms and impact in non-small cell lung cancer patients","volume":"12","author":"Nichetti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jsps.2022.06.010_b0165","unstructured":"Organization (WHO), W.H., 2017. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. WHO, http:\/\/www. who-umc. org\/graphics\/4409. pdf.[Google Scholar]."},{"key":"10.1016\/j.jsps.2022.06.010_b0170","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2013-04-460147","article-title":"Biomarkers for prediction of venous thromboembolism in cancer","volume":"122","author":"Pabinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jsps.2022.06.010_b0175","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jsps.2022.06.010_b0180","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"The Lancet"},{"issue":"25","key":"10.1016\/j.jsps.2022.06.010_b0185","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.06.010_b0190","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.jsps.2022.06.010_b0195","doi-asserted-by":"crossref","first-page":"e001719","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.jsps.2022.06.010_b0200","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jsps.2022.06.010_b0205","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jsps.2022.06.010_b0210","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/annonc\/mdx326","article-title":"Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody","volume":"28","author":"Tomita","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsps.2022.06.010_b0215","first-page":"648","article-title":"Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases","volume":"11","author":"Tsukamoto","year":"2018","journal-title":"CRO"},{"key":"10.1016\/j.jsps.2022.06.010_b0220","unstructured":"UMC | VigiBase [WWW Document], n.d. URL https:\/\/www.who-umc.org\/vigibase\/vigibase\/ (accessed 8.30.20)."},{"key":"10.1016\/j.jsps.2022.06.010_b0225","unstructured":"UMC | vigiMethods [WWW Document], n.d. URL https:\/\/www.who-umc.org\/vigibase\/vigilyze\/vigimethods\/ (accessed 5.31.21)."},{"key":"10.1016\/j.jsps.2022.06.010_b0230","unstructured":"UMC | WHO programme members [WWW Document], n.d. URL https:\/\/www.who-umc.org\/global-pharmacovigilance\/who-programme-for-international-drug-monitoring\/who-programme-members\/ (accessed 5.19.21)."},{"key":"10.1016\/j.jsps.2022.06.010_b0235","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"Watson","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.jsps.2022.06.010_b0240","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422001566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422001566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:26:57Z","timestamp":1736184417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016422001566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1319016422001566"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2022.06.010","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2022.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}